# US 2023/0140868 A1 · Compositions and methods for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0140868 A1
- Document ID: US20230140868A1
- Status: Published application
- Kind: A1
- Application number: 17/995,800
- Filed: 2021-04-23
- Published: 2023-05-11
- Earliest claimed: 2020-04-23
- Assignees: Alpha Beta Holdings, LLC
- Applicants: Alpha Beta Holdings, LLC
- Inventors: David Cheresh; Sara Weis; Stephen McCormack; Christoph Rader; Hiromi Wettersten
- Web page: https://patentgrep.com/patent/US20230140868A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- A61K 40/17: Monocytes; Macrophages
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/524: CH2 domain
- C07K 2317/53: Hinge
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to chimeric binding agents and compositions comprising the same. The invention further relates to polynucleotides encoding the chimeric binding agent and vectors and host cells comprising the same. The invention further relates to methods of using the chimeric binding agents to mediate antibody-dependent cellular cytotoxicity of epithelial cancer cells and methods of treating epithelial cell cancers.

## Claims

### Claim 1

A chimeric binding agent comprising a first domain that specifically binds to integrin αvβ3 on an epithelial cancer cell expressing at least one mesenchymal cell marker and a second domain that mediates antibody-directed cellular cytotoxicity (ADCC) by engaging a macrophage that accumulates in mesenchymal tumors.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The chimeric binding agent of claim 1, wherein the first and/or second domain is an antibody domain.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The chimeric binding agent of claim 1, wherein the first and/or second domain is a humanized or human antibody domain.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The chimeric binding agent of claim 1, which is a chimeric antibody or an antigen-binding fragment thereof.

### Claim 10 (depends on 1)

The chimeric binding agent of claim 1, wherein the first domain comprises a Fab domain of an antibody, such as an IgG antibody or an IgG4 antibody.

### Claim at position 9

11-12. (canceled)

### Claim 13 (depends on 12)

The chimeric binding agent of claim 12, wherein the first domain comprises the amino acid sequence of the light chain of hLM609-hIgG4-S228P (SEQ ID NO:2) or a sequence at least 90% identical thereto and the Fab portion of the heavy chain of hLM609-hIgG4-S228P (SEQ ID NO:3) or a sequence at least 90% identical thereto.

### Claim 14 (depends on 13)

The chimeric binding agent of claim 13, wherein the first domain comprises the amino acid sequence of the Fab portion of the heavy chain of LM609_7 (SEQ ID NO:5) or a sequence at least 90% identical thereto and the light chain of LM609_7 (SEQ ID NO:6) or a sequence at least 90% identical thereto, the Fab portion of the heavy chain of JC7U (SEQ ID NO:7) or a sequence at least 90% identical thereto and the light chain of JC7U (SEQ ID NO:8), or a sequence at least 90% identical thereto.

### Claim 15 (depends on 1)

The chimeric binding agent of claim 1, wherein the first domain further specifically binds a second antigen.

### Claim at position 13

16-21. (canceled)

### Claim 22 (depends on 1)

The chimeric binding agent of claim 1, wherein the second domain specifically binds a protein on the surface of the myeloid-derived cell, such as an Fc-gamma receptor, such as a Fc-gamma receptor I (FcγRI, CD64).

### Claim at position 15

23-24. (canceled)

### Claim 25 (depends on 1)

The chimeric binding agent of claim 1, wherein the second domain comprises an Fc domain of an antibody, such as an IgG antibody, such as an IgG4 antibody, or an Fc domain of an IgA or IgE antibody.

### Claim at position 17

26-28. (canceled)

### Claim 29 (depends on 25)

The chimeric binding agent of claim 25, wherein the second domain further comprises a hinge domain of an antibody.

### Claim 30 (depends on 29)

The chimeric binding agent of claim 29, wherein the second domain comprises the amino acid sequence of the heavy chain Fc domain and hinge domain of hLM609-hIgG4-S228P (SEQ ID NO:4) or a sequence at least 90% identical thereto.

### Claim 31 (depends on 1)

The chimeric binding agent of claim 1, wherein the amino acid sequence comprises a S228P mutation (Eu numbering system) in the hinge region.

### Claim 32 (depends on 31)

The chimeric binding agent of claim 31, comprising the amino acid sequence of the hLM609-hIgG4-S228P heavy chain (SEQ ID NO:1) and light chain (SEQ ID NO:2) or a sequence at least 90% identical thereto.

### Claim 33 (depends on 31)

The chimeric binding agent of claim 31, wherein the amino acid sequence comprises a mutation selected from:
a) S239D/A330L/I332E;
b) I332E;
c) G236A/S239D/I332E;
d) G236A;
e) N297A/E382V/M428I;
f) M252Y/S254T/T256E;
g) Q295R/L328W/A330V/P331A/I332Y/E382V/M428I;
h) L234A/L235A/P329G;
i) M428L/N434S;
j) L234A/L235A/P331S;
k) L234A/L235A/P329G/M252Y/S254T/T256E;
l) S298A/E333A/K334/A;
m) S239D/I332E;
n) G236A/S239D/A330L/I332E;
o) S239D/I332E/G236A;
p) L234Y/G236W/S298A;
q) F243L/R292P/Y300L/V305I/P396L;
r) K326W/E333 S;
s) K326A/E333A;
t) K326M/E333S;
u) C221D/D222C;
v) S267E/H268F/S324W;
w) H268F/S324W;
x) E345R
y) R435H;
z) N434A;
aa) M252Y/S254T/T256E;
ab) M428L/N434S;
ac) T252L/T/253S/T254F;
ad) E294delta/T307P/N434Y;
ae) T256N/A378V/S383N/N434Y;
af) E294delta
ag) L235E;
ah) L234A/L235A;
ai) S228P/L235E;
aj) P331 S/L234E/L225F;
ak) D265A;
al) G237A;
am) E318A;
an) E233P;
ao) G236R/L328R;
ap) H268Q/V309L/A330S/P331S;
aq) L234A/L235A/G237A/P238S/H268A/A330S/P331S;
ar) A330L;
as) D270A;
at) K322A;
au) P329A;
av) P331A;
aw V264A;
ax) F241A;
ay) N297A or G or N
az) S228P/F234A/L235A; or
ba) any combination of a) to az).

### Claim 34 (depends on 1)

A polynucleotide encoding the chimeric binding agent of claim 1.

### Claim 35 (depends on 34)

A vector comprising the polynucleotide of claim 34.

### Claim 36 (depends on 34)

A host cell comprising the polynucleotide of claim 34.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

A pharmaceutical composition comprising the chimeric binding agent of claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 28

39-40. (canceled)

### Claim 41 (depends on 1)

A kit comprising the chimeric binding agent of claim 1.

### Claim 42 (depends on 1)

A method of targeting a macrophage to a cancer cell expressing integrin αvβ3, comprising contacting the cancer cell and the macrophage with an effective amount of the chimeric binding agent of claim 1.

### Claim at position 31

43-45. (canceled)

### Claim 46 (depends on 1)

A method of treating a cancer expressing integrin αvβ3 in a subject in need thereof, comprising administering a therapeutically effective amount of the chimeric binding agent of claim 1 to the subject, thereby treating the cancer.

### Claim 47

(canceled)

### Claim 48 (depends on 1)

A method of treating a cancer in a subject in need thereof, comprising the steps of:
a) selecting a subject having cancer cells that are enriched for integrin αvβ3 and enriched for macrophages; and
b) administering a therapeutically effective amount of the chimeric binding agent of claim 1 to the subject, thereby treating the cancer.

### Claim at position 35

49-62. (canceled)
